LLY

1,050.93

-0.03%↓

JNJ

246.53

+0.11%↑

ABBV

228.47

+0.03%↑

NVS

166.89

+1.29%↑

MRK

123.91

+0.58%↑

LLY

1,050.93

-0.03%↓

JNJ

246.53

+0.11%↑

ABBV

228.47

+0.03%↑

NVS

166.89

+1.29%↑

MRK

123.91

+0.58%↑

LLY

1,050.93

-0.03%↓

JNJ

246.53

+0.11%↑

ABBV

228.47

+0.03%↑

NVS

166.89

+1.29%↑

MRK

123.91

+0.58%↑

LLY

1,050.93

-0.03%↓

JNJ

246.53

+0.11%↑

ABBV

228.47

+0.03%↑

NVS

166.89

+1.29%↑

MRK

123.91

+0.58%↑

LLY

1,050.93

-0.03%↓

JNJ

246.53

+0.11%↑

ABBV

228.47

+0.03%↑

NVS

166.89

+1.29%↑

MRK

123.91

+0.58%↑

Home・Akcijų sąrašas・Vivani Medical

Vivani Medical

Atidarymo kaina

1.22 -2.4

Pirkti Parduoti

Apžvalga

Akcijų kainos pasikeitimas

24 val.

Dabar

Min

1.21

Max

1.26

Pagrindiniai rodikliai
By Trading Economics
Darbuotojai	37

Dividendai
By Dow Jones
Kitas uždarbis	2026-03-30

Rinkos statistika
By TradingEconomics
Rinkos kapitalizacija	-20M 84M
Ankstesnė atidarymo kaina	3.62
Ankstesnė uždarymo kaina	1.22

Vivani Medical Grafikas

Ankstesni rezultatai nėra patikimas būsimų rezultatų rodiklis.

Susijusios naujienos

2026-02-23 22:53; UTC

Įsigijimai, susijungimai, perėmimai

Keurig Dr Pepper Raises Additional $1.5 Billion in Deal to Split Company

2026-02-23 22:36; UTC

Uždarbis

Kratos Defense & Security Solutions 4Q Profit Rises; Sees Federal Shutdown Denting 1Q -- Update

2026-02-23 22:32; UTC

Uždarbis

Woodside Energy Fiscal Year Net Profit Falls 24%

2026-02-23 23:58; UTC

Rinkos pokalbiai

Uždarbis

Plenty of Questions for Woodside Despite Well-Guided Result -- Market Talk

2026-02-23 23:58; UTC

Rinkos pokalbiai

Uždarbis

Global Energy Roundup: Market Talk

2026-02-23 23:47; UTC

Rinkos pokalbiai

Scentre's Share Price Slips as Earnings Guidance Underwhelms -- Market Talk

2026-02-23 23:43; UTC

Rinkos pokalbiai

Gold Edges Higher Amid Ongoing Tariff Risks -- Market Talk

2026-02-23 23:41; UTC

Įsigijimai, susijungimai, perėmimai

Crescent Capital Partners Owns 53% of ClearView Wealth

2026-02-23 23:40; UTC

Įsigijimai, susijungimai, perėmimai

ClearView Wealth Says Crescent Capital Partners Intends to Support Deal

2026-02-23 23:40; UTC

Įsigijimai, susijungimai, perėmimai

ClearView Wealth Says Directors Unanimously Recommend Shareholders Vote in Favor of Deal

2026-02-23 23:40; UTC

Rinkos pokalbiai

Nikkei May Rise as Investors Assess Tariff Developments -- Market Talk

2026-02-23 23:40; UTC

Įsigijimai, susijungimai, perėmimai

ClearView Wealth Says Zurich Insurance Offering A$0.65/Share in Cash

2026-02-23 23:39; UTC

Įsigijimai, susijungimai, perėmimai

ClearView Wealth Agrees to Takeover by Zurich Insurance Group Unit

2026-02-23 23:31; UTC

Uždarbis

United Overseas Bank 2025 Total Dividend S$1.56/Shr >U11.SG

2026-02-23 23:31; UTC

Uždarbis

United Overseas Bank Proposes Final Dividend of S$0.71/Shr Vs. S$0.92/Shr >U11.SG

2026-02-23 23:28; UTC

Uždarbis

United Overseas Bank 4Q Net Interest Income S$2.35B Vs. S$2.45B >U11.SG

2026-02-23 23:28; UTC

Uždarbis

United Overseas Bank 4Q Oper Pft S$1.76B Vs. Pft S$1.88B >U11.SG

2026-02-23 23:28; UTC

Uždarbis

United Overseas Bank 4Q Total Income S$3.29B Vs. S$3.46B >U11.SG

2026-02-23 23:27; UTC

Uždarbis

United Overseas Bank 4Q Net S$1.41B Vs. Net S$1.52B >U11.SG

2026-02-23 23:24; UTC

Rinkos pokalbiai

Major Miners On Whole Delivered Positive Earnings Season -- Market Talk

2026-02-23 22:38; UTC

Įsigijimai, susijungimai, perėmimai

Keurig Dr Pepper Raises Additional $1.5B in Deal to Split Company

2026-02-23 22:31; UTC

Uždarbis

Hims & Hers Stock Falls. Why Earnings Are Underwhelming Investors. -- Barrons.com

2026-02-23 22:24; UTC

Uždarbis

Viva Energy Energy & Infrastructure Ebitda A$93 Million

2026-02-23 22:22; UTC

Uždarbis

Viva Energy FY Commercial & Industrial Ebitda A$460.5 Million

2026-02-23 22:22; UTC

Uždarbis

Viva Energy FY Convenience & Mobility Ebitda A$197.4 Million

2026-02-23 22:22; UTC

Uždarbis

Viva Energy FY Underlying Ebitda A$700.9 Million

2026-02-23 22:22; UTC

Uždarbis

Viva Energy Final Dividend 3.94 Australian Cents/Security

2026-02-23 22:21; UTC

Uždarbis

Viva Energy FY Revenue A$28.53 Billion, Down 1.1%

2026-02-23 22:21; UTC

Uždarbis

Viva Energy FY Replacement-Cost Net Profit A$183.6 Million, Down 28%

2026-02-23 22:20; UTC

Uždarbis

Viva Energy FY Historical-Cost Net Loss A$421.1 Million

Akcijų palyginimas

Kainos pokytis

Vivani Medical Prognozė

Bendras įvertinimas

By TipRanks

0 ratings

Pirkti

Laikyti

Parduoti

Remiantis 0 analitikų, pateikusių Vivani Medical akcijų reitingus – Dist per pastaruosius 3 mėnesius.

Finansinės naujienos

Apie bendrovę Vivani Medical

Vivani Medical, Inc., a preclinical stage biopharmaceutical company, engages in the development of miniaturized and subdermal implants that treat chronic diseases. The company uses its NanoPortal implant technology to develop and potentially commercialize drug implant candidates in the treatment of chronic disease, medication non-adherence. Its pipeline includes NPM-115, a high-dose exenatide implant candidate is in preclinical stage development for the treatment of chronic weight management in patients with obesity or overweight; NPM-119, an exenatide implant candidate is in preclinical stage development for the treatment of patients with type 2 diabetes; NPM-139, a miniature, subdermal GLP-1 implant in development for chronic weight management; and OKV-119, an exenatide implant is under development for metabolic diseases in cats including for the treatment of obesity and diabetes. The company is headquartered in Alameda, California.